首页> 外国专利> Use of Prourokinase and Variants Thereof in Facilitated Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction

Use of Prourokinase and Variants Thereof in Facilitated Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction

机译:原尿激酶及其变种在急性心肌梗死患者经皮冠状动脉介入治疗中的应用

摘要

In the field of biological medicines, a use of prourokinase (proUK) and variants thereof in facilitated percutaneous coronary intervention (PCI) in patients with acute myocardial infarction is provided. The use includes: within 6 hrs after a patient is afflicted with accurate myocardial infarction (AMI), firstly, performing thrombolytic therapy with proUK or variants thereof, and then, performing a PCI operation, to dredge the infarction related artery (IRA) as soon as possible, and re-establish an effective forward blood flow, such that an ischemic myocardium is reperfused. According to the present invention, the facilitated PCI for treatment of AMI with the proUK or variants thereof has an effect superior to that of direct PCI.
机译:在生物医学领域,提供了原尿激酶(proUK)及其变体在急性心肌梗死患者的促进的经皮冠状动脉介入治疗(PCI)中的用途。用途包括:在患者遭受精确的心肌梗塞(AMI)后的6小时内,首先,使用proUK或其变体进行溶栓治疗,然后进行PCI手术,以尽快疏通梗死相关动脉(IRA)尽可能地,并重新建立有效的正向血流,以便缺血性心肌被重新灌注。根据本发明,用于用proUK或其变体治疗AMI的促进性PCI具有优于直接PCI的效果。

著录项

  • 公开/公告号US2011229454A1

    专利类型

  • 公开/公告日2011-09-22

    原文格式PDF

  • 申请/专利权人 JIANNING LIU;

    申请/专利号US20080935161

  • 发明设计人 JIANNING LIU;

    申请日2008-04-01

  • 分类号A61K38/49;A61P7/02;

  • 国家 US

  • 入库时间 2022-08-21 18:14:38

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号